Detection of activated K-ras in non-small cell lung cancer by membrane array: A comparison with direct sequencing

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 17-24

  Chong, Inn Wen ^a   Chang, Mei Yin ^b   Sheu, Chau Chyun ^a   Wang, Cheng Yuan ^a   Hwang, Jhi Jhu ^a   Huang, Ming Shyan ^a   Lin, Shiu Ru ^b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Direct sequencing; K ras; Membrane array; Mutation; Non small cell lung cancer; Tumor markers

Indexed keywords

DNA;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; DNA MICROARRAY; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TAIWAN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; TAIWAN;

EID: 34548008404     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.17     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Friday BB and Adjei AA: K-ras as a target for cancer therapy. Biochim Biophys Acta 1756: 127-144, 2005. (Pubitemid 41773139)
3. Rodenhuis S: ras and human tumors. Semin Cancer Biol 3: 241-247, 1992.
4. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N and Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-935, 1987. (Pubitemid 17147935)
5. Rodenhuis S and Slebos RJ: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: S2665-S2669, 1992.
6. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ and Rodenhuis S: Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 83: 1024-1027, 1991.
7. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, van Bodegom PC and Bos JL: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738-5741, 1988.
8. Huncharek M, Muscat J and Geschwind JF: K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20: 1507-1510, 1999. (Pubitemid 29385437)
9. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ and Sculier JP: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139, 2005. (Pubitemid 40188446)
10. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL and Shih I: Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 10: 6432-6436, 2004. (Pubitemid 39346537)
11. Von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE and Boss GR: Ras activation in human breast cancer. Breast Cancer Res Treat 62: 51-62, 2000. (Pubitemid 30609563)
12. Galiana C, Lozano JC, Bancel B, Nakazawa H and Yamasaki H: High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog 14: 286-293, 1995. (Pubitemid 26109872)
13. Coleman WB, Throneburg DB, Grisham JW and Smith GJ: Overexpression of c-K-ras, c-N-ras and transforming growth factor beta co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines. Carcinogenesis 15: 1005-1012, 1994. (Pubitemid 24156903)
14. Lin SR, Tsai JH, Yang YC and Lee SC: Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer 77: 1060-1065, 1998. (Pubitemid 28116275)
15. Chen YF, Chiu HH, Wu CH, Wang JY, Chen FM, Tzou WH, Shin SJ and Lin SR: Retinoblastoma protein (pRB) was significantly phosphorylated through a Ras-to-MAPK pathway in mutant K-ras stably transfected human adrenocortical cells. DNA Cell Biol 22: 657-664, 2003. (Pubitemid 37357736)
16. Lin SR, Hsu CH, Tsai JH, Wang JY, Hsieh TJ and Wu CH: Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours. Br J Cancer 82: 1035-1040, 2000. (Pubitemid 30128856)
17. Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL and Lin SR: Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 229: 115-122, 2005. (Pubitemid 41262547)
18. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
19. Sambrook J, Fritsch EF and Maniatis T: Molecular cloning: a laboratory manual. In: Ford N and Nolan C (eds). Cold Spring Harbor Laboratories Press, NY, pp6.22-6.34, 1989.
20. Gao HG, Chen JK, Stewart J, Song B, Rayappa C, Whong WZ and Ong T: Distribution of p53 and K-ras mutations in human lung cancer tissues. Carcinogenesis 18: 473-478, 1997. (Pubitemid 28132482)
21. Vachtenheim J, Horakova I, Novotna H, Opaalka P and Roubkova H: Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Clin Cancer Res 1: 359-365, 1995.
22. Gealy R, Zhang L, Siegfried JM, Luketich JD and Keohavong P: Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and non-smoking women. Cancer Epidemiol Biomarkers Prev 8: 297-302, 1999. (Pubitemid 29193900)
23. Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ and Sidransky D: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530, 2001. (Pubitemid 32947838)
24. Westra WH, Slebos RJ, Offerhaus GJ, Goodman SN, Evers SG, Kensler TW, Askin FB, Rodenhuis S and Hruban RH: K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72: 432-438, 1993. (Pubitemid 23193449)
25. Ko YC, Cheng LS, Lee CH, Huang JJ, Huang MS, Kao EL, Wang HZ and Lin HJ: Chinese food cooking and lung cancer in women non-smokers. Am J Epidemiol 151: 140-147, 2000. (Pubitemid 30463644)
26. Ko YC, Lee CH, Chen MJ, Huang CC, Chang WY, Lin HJ, Wang HZ and Chang PY: Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 26: 24-31, 1997. (Pubitemid 27129565)
27. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, Su JM and Lee H: The association of human papillomavirus 16/18 infection with lung cancer among non-smoking Taiwanese women. Cancer Res 61: 2799-2803, 2001.
28. Destro A, Bianchi P, Alloisio M, Laghi L, Di GS, Malesci A, Cariboni U, Gribaudi G, Bulfamante G, Marchetti A, Bosari S, Infante M, Ravasi G and Roncalli M: K-ras and p16(INK4A) alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 44: 23-32, 2004. (Pubitemid 38317259)
29. Keohavong P, Lan Q, Gao WM, Zheng KC, Mady HH, Melhem MF and Mumford JL: Detection of p53 and K-ras mutations in sputum of individuals exposed to smoky coal emissions in Xuan Wei County, China. Carcinogenesis 26: 303-308, 2005. (Pubitemid 40246551)
30. Minamoto T, Mai M and Ronai Z: K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas and lung cancers - a review. Cancer Detect Prev 24: 1-12, 2000. (Pubitemid 30152735)
31. Nakajima E, Hirano T, Konaka C, Ikeda N, Kawate N, Ebihara Y and Kato H: K-ras mutation in sputum of primary lung cancer patients does not always reflect that of cancerous cells. Int J Oncol 18: 105-110, 2001.
32. Ronai Z, Yabubovskaya MS, Zhang E and Belitsky GA: K-ras mutation in sputum of patients with or without lung cancer. J. Cell Biochem Suppl 25: S172-S176, 1996.
33. Zhang LF, Gao WM, Gealy R, Weissfeld J, Elder E, Whiteside TL and Keohavong P: Comparison of K-ras gene mutations in tumour and sputum DNA of patients with lung cancer. Biomarkers 8: 156-161, 2003. (Pubitemid 36747951)
34. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J and Sidransky D: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91: 332-339, 1999. (Pubitemid 29102332)
35. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus H: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: E17, 2005.
36. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S and Hillan KJ: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909, 2005.